Effect of Aortic Valve Type on Patients Who Undergo Type A Aortic Dissection Repair.


Journal

Seminars in thoracic and cardiovascular surgery
ISSN: 1532-9488
Titre abrégé: Semin Thorac Cardiovasc Surg
Pays: United States
ID NLM: 8917640

Informations de publication

Date de publication:
2022
Historique:
received: 26 03 2021
accepted: 06 04 2021
pubmed: 14 5 2021
medline: 7 6 2022
entrez: 13 5 2021
Statut: ppublish

Résumé

Aortic valve replacement (AVR) is common in the setting of type A aortic dissection (TAAD) repair. Here, we evaluated the association between prosthesis choice and patient outcomes in an international patient cohort. We reviewed data from the International Registry of Acute Aortic Dissection (IRAD) interventional cohort to examine the relationship between valve choice and short- and mid-term patient outcomes. Between January 1996 and March 2016, 1290 surgically treated patients with TAAD were entered into the IRAD interventional cohort. Of those, 364 patients undergoing TAAD repair underwent aortic valve replacement (AVR; mean age, 57 years). The mechanical valve cohort consisted of 189 patients, of which 151 (79.9%) had a root replacement. The nonmechanical valve cohort consisted of 5 patients who received homografts and 160 patients who received a biologic AVR, with a total of 118 (71.5%) patients who underwent root replacements. The mean follow-up time was 2.92 ± 1.75 years overall (2.46 ± 1.69 years for the mechanical valve cohort and 3.48 ± 1.8 years for the nonmechanical valve cohort). After propensity matching, Kaplan-Meier estimates of 4-year survival rates after surgery were 64.8% in the mechanical valve group compared with 74.7% in the nonmechanical valve group (p = 0.921). A stratified Cox model for 4-year mortality showed no difference in hazard between valve types after adjusting for the propensity score (p = 0.854). A biologic valve is a reasonable option in patients with TAAD who require AVR. Although this option avoids the potential risks of anticoagulation, long-term follow up is necessary to assess the effect of reoperations or transcatheter interventions for structural valve degeneration.

Identifiants

pubmed: 33984483
pii: S1043-0679(21)00197-0
doi: 10.1053/j.semtcvs.2021.04.003
pii:
doi:

Substances chimiques

Biological Products 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-487

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Gabriel Loor (G)

Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, Minn; Division of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas; Division of Cardiothoracic Transplantation and Circulatory Support, Texas Heart Institute, Houston, Texas. Electronic address: Gabriel.Loor@bcm.edu.

Thomas G Gleason (TG)

Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Penn.

Truls Myrmel (T)

Department of Thoracic and Cardiovascular Surgery, Tromso University Hospital, Tromso, Norway.

Amit Korach (A)

Department of Cardiothoracic Surgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Santi Trimarchi (S)

Department of Vascular Surgery, IRCCS Policlinico San Donato, San Donato, Italy.

Nimesh D Desai (ND)

Department of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Penn.

Joseph E Bavaria (JE)

Department of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Penn.

Carlo de Vincentiis (C)

Department of Vascular Surgery, IRCCS Policlinico San Donato, San Donato, Italy.

Maral Ouzounian (M)

Division of Cardiac Surgery, Toronto General Hospital, Toronto, Ontario, Canada.

Udo Sechtem (U)

Division of Cardiology, Robert-Bosch Krankenhaus, Stuttgart, Germany.

Daniel G Montgomery (DG)

Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich.

Edward P Chen (EP)

Division of Cardiothoracic Surgery, Emory University, Atlanta, Georgia.

Hersh Maniar (H)

Division of Cardiothoracic Surgery, Department of Cardiovascular Surgery, Washington University, St. Louis, Missouri.

Thoralf M Sundt (TM)

Thoracic Aortic Center, Massachusetts General Hospital, Boston, Mass.

Himanshu Patel (H)

Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH